Tyme Technologies (Tyme Technologies) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 06, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Tyme Technologies's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Tyme Technologies's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Tyme Technologies's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyme Technologies's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's Margin of Safety % (DCF Dividends Based) falls into.

Tyme Technologies Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyme Technologies (Tyme Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921

Website

https://www.tymeinc.com

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Executives

Michael Demurjian	director, 10 percent owner, officer: Chief Operating Officer	157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman	director, 10 percent owner, officer: CEO and Chief Science Officer	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl	director	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido	officer: Chief Financial Officer	C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini	officer: Corporate Controller	17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry	director	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M	officer: Acting Chief Medical Officer	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman	officer: EVP, Product Development	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor	officer: President and CFO	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin	officer: Chief Operating Officer	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105